Silicon Hills Wealth Management News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Silicon hills wealth management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Silicon Hills Wealth Management Today - Breaking & Trending Today

Stifel Nicolaus Upgrades Editas Medicine (NASDAQ:EDIT) to Buy

Stifel Nicolaus upgraded shares of Editas Medicine (NASDAQ:EDIT – Free Report) from a hold rating to a buy rating in a report published on Thursday morning, Marketbeat reports. They currently have $17.00 target price on the stock, up from their prior target price of $9.00. Other equities research analysts have also recently issued research reports […] ....

Raymond James , Stifel Nicolaus , Baisong Mei , Editas Medicine Company Profile , Congress Asset Management Co , Silicon Hills Wealth Management , Cantor Fitzgerald , Profund Advisors , Securities Exchange Commission , Editas Medicine Inc , Editas Medicine , Free Report , Get Free Report , Exchange Commission , Hills Wealth Management , Asset Management , Leber Congenital Amaurosis , Editas Medicine Daily , Nasdaq Edit ,

Editas Medicine (NASDAQ:EDIT) Rating Increased to Buy at Stifel Nicolaus

Stifel Nicolaus upgraded shares of Editas Medicine (NASDAQ:EDIT – Free Report) from a hold rating to a buy rating in a report released on Thursday morning, MarketBeat.com reports. They currently have $17.00 target price on the stock, up from their previous target price of $9.00. A number of other research analysts have also weighed in […] ....

Raymond James , Baisong Mei , Stifel Nicolaus , Editas Medicine Inc , Cantor Fitzgerald , Securities Exchange Commission , Silicon Hills Wealth Management , Congress Asset Management Co , Profund Advisors , Editas Medicine , Free Report , Get Free Report , Exchange Commission , Hills Wealth Management , Asset Management , Leber Congenital Amaurosis , Editas Medicine Daily , Nasdaq Edit ,

Editas Medicine (NASDAQ:EDIT) Stock Rating Reaffirmed by Oppenheimer

Oppenheimer restated their market perform rating on shares of Editas Medicine (NASDAQ:EDIT – Free Report) in a research report report published on Thursday morning, Benzinga reports. They currently have a $12.00 price target on the stock. EDIT has been the subject of a number of other research reports. StockNews.com lowered Editas Medicine from a hold […] ....

Baisong Mei , Gilmore Neil Oneill , Raymond James , Congress Asset Management Co , Dimensional Fund Advisors , Silicon Hills Wealth Management , Editas Medicine Company Profile , Securities Exchange Commission , Editas Medicine Inc , Editas Medicine , Free Report , Medicine Trading Down , Get Free Report , Neilo Neill , Exchange Commission , Hills Wealth Management , Asset Management , Fund Advisors , Leber Congenital Amaurosis , Editas Medicine Daily , Nasdaq Edit , Reiterated Rating , Oppenheimer Holdings Inc ,

Editas Medicine's (EDIT) "Market Perform" Rating Reiterated at Oppenheimer

Editas Medicine's (EDIT) "Market Perform" Rating Reiterated at Oppenheimer
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Gilmore Neil Oneill , Raymond James , Baisong Mei , Congress Asset Management Co , Editas Medicine Company Profile , Securities Exchange Commission , Silicon Hills Wealth Management , Editas Medicine Inc , Dimensional Fund Advisors , Editas Medicine , Get Free Report , Neilo Neill , Exchange Commission , Hills Wealth Management , Asset Management , Fund Advisors , Leber Congenital Amaurosis , Editas Medicine Daily ,